[go: up one dir, main page]

ATE472604T1 - Verfahren zur herstellung von proteinen - Google Patents

Verfahren zur herstellung von proteinen

Info

Publication number
ATE472604T1
ATE472604T1 AT03750495T AT03750495T ATE472604T1 AT E472604 T1 ATE472604 T1 AT E472604T1 AT 03750495 T AT03750495 T AT 03750495T AT 03750495 T AT03750495 T AT 03750495T AT E472604 T1 ATE472604 T1 AT E472604T1
Authority
AT
Austria
Prior art keywords
producing proteins
proteins
producing
transient expression
secreted protein
Prior art date
Application number
AT03750495T
Other languages
English (en)
Inventor
Gilbert Gorr
Heike Launhardt
Birgit Berg
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020020382 external-priority patent/EP1398383A1/de
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Application granted granted Critical
Publication of ATE472604T1 publication Critical patent/ATE472604T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT03750495T 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen ATE472604T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020020382 EP1398383A1 (de) 2002-09-12 2002-09-12 Verfahren zur Herstellung von Proteinen
EP03015881 2003-07-11
PCT/EP2003/009959 WO2004024927A1 (en) 2002-09-12 2003-09-08 Protein production method

Publications (1)

Publication Number Publication Date
ATE472604T1 true ATE472604T1 (de) 2010-07-15

Family

ID=31995519

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750495T ATE472604T1 (de) 2002-09-12 2003-09-08 Verfahren zur herstellung von proteinen

Country Status (9)

Country Link
EP (1) EP1539966B1 (de)
AT (1) ATE472604T1 (de)
AU (1) AU2003270152A1 (de)
DE (1) DE60333201D1 (de)
DK (1) DK1539966T3 (de)
ES (1) ES2347325T3 (de)
PT (1) PT1539966E (de)
SI (1) SI1539966T1 (de)
WO (1) WO2004024927A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2380910T3 (en) 2003-11-05 2015-10-19 Roche Glycart Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
RU2488597C2 (ru) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
AR055137A1 (es) 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
SE529610C2 (sv) 2006-02-13 2007-10-02 Alfa Laval Corp Ab Centrifugalseparator
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
CA2770174A1 (en) 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
KR101780131B1 (ko) 2010-08-13 2017-09-19 로슈 글리카트 아게 항-fap 항체 및 이의 사용 방법
CN103168049B (zh) 2010-08-13 2015-10-07 罗切格利卡特公司 抗生腱蛋白-c a2抗体及使用方法
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
PT2681244T (pt) 2011-03-02 2018-01-24 Roche Glycart Ag Anticorpos do cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2748202B1 (de) 2011-08-23 2018-07-04 Roche Glycart AG Bispezifische antigenbindende moleküle
CN103890006A (zh) 2011-08-23 2014-06-25 罗切格利卡特公司 抗mcsp抗体
PL3434695T3 (pl) 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
EP2961772A1 (de) 2013-02-26 2016-01-06 Roche Glycart AG Anti-mcsp-antikörper
CN107921090A (zh) 2015-04-06 2018-04-17 苏伯多曼有限责任公司 含有从头结合结构域的多肽及其用途
US11142565B2 (en) 2015-09-24 2021-10-12 Abvitro Llc Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
EP3178848A1 (de) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
JP2019515874A (ja) 2016-03-01 2019-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改変された細胞死誘導を有するオビヌツズマブ変異体
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
EP3252078A1 (de) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
MX2019012793A (es) 2017-04-27 2020-02-13 Tesaro Inc Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
EP3630829A1 (de) 2017-06-02 2020-04-08 H. Hoffnabb-La Roche Ag Typ-ii-anti-cd20-antikörper und anti-cd20/cd3-bispezifischer antikörper zur krebsbehandlung
MX2020004935A (es) 2017-11-14 2020-09-25 Arcellx Inc Terapias con celulas inmunitarias multifuncionales.
AU2018369639C1 (en) 2017-11-14 2025-04-03 Arcellx, Inc. D-domain containing polypeptides and uses thereof
EP3737692A4 (de) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. Calreticulin-bindende konstrukte und gentechnisch veränderte t-zellen zur behandlung von krankheiten
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7403479B2 (ja) 2018-06-03 2023-12-22 ランカプ バイオ ベータ リミテッド Ceacam5およびcd47に対する二重特異性抗体
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
CN109295068B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP2及应用
CN109234284B (zh) * 2018-09-14 2021-04-09 昆明理工大学 一种三七类甜蛋白基因PnTLP5及应用
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
EP3831849A1 (de) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispezifische antikörper gegen ceacam5 und cd47
EP4084823A4 (de) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
EP4229068A1 (de) 2020-10-13 2023-08-23 Avitide LLC Affinitätsligandbibliotheken von drei helixbündelproteinen und verwendungen davon
WO2022081775A1 (en) 2020-10-13 2022-04-21 Avitide LLC Aav8 affinity agents
CN117241866A (zh) 2021-02-19 2023-12-15 艾维泰有限责任公司 Aav2亲和剂
MX2023011110A (es) 2021-03-26 2023-11-23 Arcellx Inc Terapias de celulas inmunitarias multifuncionales.
CN117222412A (zh) 2021-04-23 2023-12-12 豪夫迈·罗氏有限公司 Nk细胞接合剂相关的不良反应的预防或减轻
CN118984834A (zh) 2021-12-24 2024-11-19 阿维泰德有限责任公司 Ch1结构域亲和配体和试剂
EP4562022A1 (de) 2022-07-29 2025-06-04 Repligen Corporation Affinitätsagent mit einem ligand zur bindung von vce und mit seq id no: 1
CA3266644A1 (en) 2022-09-09 2024-03-14 Repligen Corporation AFFINITY AGENTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947290A1 (de) * 1999-10-01 2001-04-19 Greenovation Pflanzenbiotechno Verfahren zur Herstellung proteinöser Substanzen

Also Published As

Publication number Publication date
SI1539966T1 (sl) 2010-10-29
EP1539966A1 (de) 2005-06-15
AU2003270152A1 (en) 2004-04-30
DK1539966T3 (da) 2010-10-04
PT1539966E (pt) 2010-09-14
DE60333201D1 (de) 2010-08-12
WO2004024927A1 (en) 2004-03-25
ES2347325T3 (es) 2010-10-28
EP1539966B1 (de) 2010-06-30

Similar Documents

Publication Publication Date Title
ATE472604T1 (de) Verfahren zur herstellung von proteinen
DE59610898D1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
ATE348111T1 (de) Verfahren zur herstellung von humanem serumalbumin unter verwendung eines aufwarmschrittes
ATE517185T1 (de) Methoden zur herstellung von pflanzen mit erhöhtem ölsäuregehalt
DE602004008776D1 (de) Vorrichtung und verfahren zur konfiguration von sprachlesern unter verwendung semantischer analyse
ATE490309T1 (de) Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
SG149000A1 (en) Gag binding proteins
ATE326145T1 (de) Verfahren zur herstellung von frischkäse mit sojaproteinzusatz
DE60036636D1 (de) Rinder-kollagen und verfahren zur herstelling rekombinantes gelatin
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE291936T1 (de) Kunsthaar und verfahren zur herstellung von haarersatz
DE60228588D1 (de) Verfahren zur konstruktion von künstlicher vegetation nach dem vorbild von natürlichem laub
ATE351911T1 (de) Verfahren zur herstellung von heterologen proteinen in fungi
DE60027932D1 (de) Verfahren zur herstellung von proteinhydrolysaten
ATE387497T1 (de) Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen
ATE232904T1 (de) Verfahren zur herstellung proteinöser substanzen
ATE550437T1 (de) Verfahren zur expression und reinigung von immunotoxinen
ATE499845T1 (de) Weisses proteinklebermehl und verfahren für seine verwendung
ATE308334T1 (de) Verfahren zur herstellung von tocotrienol- angereicherten präparationen
DE69630524D1 (de) Methoden zur aufreinigung von authentischem igf aus hefewirtszellen
ATE400662T1 (de) Herstellung von frostschutzprotein
ATE299944T1 (de) System zur herstellung von proteinen
ATE538209T1 (de) L-threonin herstellendes bakterium und verfahren zur herstellung von l-threonin
ATE319837T1 (de) Verfahren zur herstellung von rekombinantem trypsin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1539966

Country of ref document: EP